
Andrew L Clark

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1611046/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. European Heart Journal, 2006, 27, 569-581.	2.2	203
2	Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. European Journal of Heart Failure, 2001, 3, 381-387.	7.1	148
3	Is Heart Rate Important for Patients With Heart Failure in Atrial Fibrillation?. JACC: Heart Failure, 2014, 2, 213-220.	4.1	120
4	Prevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients With Chronic Heart Failure. JAMA Cardiology, 2016, 1, 539.	6.1	117
5	Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value. European Heart Journal, 2015, 36, 733-742.	2.2	109
6	Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure. European Journal of Heart Failure, 2019, 21, 904-916.	7.1	100
7	Identification of Frailty in ChronicÂHeartÂFailure. JACC: Heart Failure, 2019, 7, 291-302.	4.1	92
8	Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. European Journal of Heart Failure, 2000, 2, 209-212.	7.1	89
9	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart â€~OMics' in AGEing (HOMAGE) randomized clinical trial. European Heart Journal, 2021, 42, 684-696.	2.2	77
10	Cardiac Dysfunction, Congestion and Loop Diuretics: their Relationship to Prognosis in Heart Failure. Cardiovascular Drugs and Therapy, 2016, 30, 599-609.	2.6	75
11	Sacubitril/valsartan: beyond natriuretic peptides. Heart, 2017, 103, 1569-1577.	2.9	72
12	Causes and treatment of oedema in patients with heart failure. Nature Reviews Cardiology, 2013, 10, 156-170.	13.7	65
13	What proportion of patients with chronic heart failure are eligible for sacubitril–valsartan?. European Journal of Heart Failure, 2017, 19, 768-778.	7.1	64
14	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. Circulation: Heart Failure, 2019, 12, e005897.	3.9	63
15	Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose–response meta-analysis. Clinical Research in Cardiology, 2019, 108, 119-132.	3.3	62
16	Change in renal function associated with drug treatment in heart failure: national guidance. Heart, 2019, 105, 904-910.	2.9	62
17	High-sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death. Cardiovascular Research, 2020, 116, 91-100.	3.8	58
18	Fluid Management In Patients With Chronic Heart Failure. Cardiac Failure Review, 2015, 1, 90.	3.0	56

#	Article	IF	CITATIONS
19	Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance. European Journal of Heart Failure, 2018, 20, 1426-1435.	7.1	56
20	The effects of shortâ€ŧerm omission of daily medication on the pathophysiology of heart failure. European Journal of Heart Failure, 2017, 19, 643-649.	7.1	53
21	The prevalence and incidence of left bundle branch block in ambulant patients with chronic heart failure. European Journal of Heart Failure, 2008, 10, 696-702.	7.1	50
22	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC: Heart Failure, 2021, 9, 268-277.	4.1	46
23	Clinical trials update: IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II, APRICOT and HEART. European Journal of Heart Failure, 2000, 2, 455-460.	7.1	44
24	Malnutrition, congestion and mortality in ambulatory patients with heart failure. Heart, 2019, 105, 297-306.	2.9	44
25	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proofâ€ofâ€concept, randomised, precisionâ€medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. European Journal of Heart Failure. 2020. 22. 1711-1723.	7.1	43
26	The Vital Role of the Right Ventricle in the Pathogenesis of Acute Pulmonary Edema. American Journal of Cardiology, 2015, 115, 992-1000.	1.6	41
27	Prognostic significance of ultrasound-assessed jugular vein distensibility in heart failure. Heart, 2015, 101, 1149-1158.	2.9	41
28	The Long-Term Prognostic Significance of 6-Minute Walk Test Distance in Patients with Chronic Heart Failure. BioMed Research International, 2014, 2014, 1-7.	1.9	40
29	The impact of malnutrition on short-term morbidity and mortality in ambulatory patients with heart failure. American Journal of Clinical Nutrition, 2021, 113, 695-705.	4.7	40
30	Low skeletal muscle mass is associated with low aerobic capacity and increased mortality risk in patients with coronary heart disease – a CARE CR study. Clinical Physiology and Functional Imaging, 2019, 39, 93-102.	1.2	35
31	Revisiting a classical clinical sign: Jugular venous ultrasound. International Journal of Cardiology, 2014, 170, 364-370.	1.7	33
32	The control of adrenergic function in heart failure: therapeutic intervention. , 2000, 5, 101-114.		32
33	Outcomes Related to First-Degree Atrioventricular Block and Therapeutic Implications in Patients With Heart Failure. JACC: Clinical Electrophysiology, 2016, 2, 181-192.	3.2	29
34	Nonâ€invasive measurement of right atrial pressure by nearâ€infrared spectroscopy: preliminary experience. A report from the <scp>SICAâ€HF</scp> study. European Journal of Heart Failure, 2017, 19, 883-892.	7.1	28
35	Oral modified release morphine for breathlessness in chronic heart failure: a randomized placeboâ€controlled trial. ESC Heart Failure, 2019, 6, 1149-1160.	3.1	28
36	Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. Clinical Research in Cardiology, 2017, 106, 711-721.	3.3	27

#	Article	IF	CITATIONS
37	Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Heart Failure Reviews, 2021, 26, 1421-1435.	3.9	26
38	ls taking part in clinical trials good for your health? A cohort study. European Journal of Heart Failure, 2009, 11, 1078-1083.	7.1	25
39	Prevalence, predictors, and prognostic implications of PR interval prolongation in patients with heart failure. Clinical Research in Cardiology, 2018, 107, 108-119.	3.3	25
40	Prescribing Patterns to Optimize HeartÂRate. JACC: Heart Failure, 2015, 3, 224-230.	4.1	24
41	Exploring quality of life in patients with and without heart failure. International Journal of Cardiology, 2016, 202, 676-684.	1.7	23
42	Does home oxygen therapy (HOT) in addition to standard care reduce disease severity and improve symptoms in people with chronic heart failure? A randomised trial of home oxygen therapy for patients with chronic heart failure. Health Technology Assessment, 2015, 19, 1-120.	2.8	23
43	Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review. International Journal of Cardiology, 2015, 196, 61-69.	1.7	22
44	Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and metaâ€analysis. ESC Heart Failure, 2017, 4, 40-45.	3.1	22
45	Hypochloraemia in Patients with Heart Failure: Causes and Consequences. Cardiology and Therapy, 2020, 9, 333-347.	2.6	22
46	Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan. European Journal of Heart Failure, 2018, 20, 1179-1190.	7.1	21
47	Ventilatory capacity and exercise tolerance in patients with chronic stable heart failure. European Journal of Heart Failure, 2000, 2, 47-51.	7.1	20
48	Agreement and Classification Performance of Malnutrition Tools in Patients with Chronic Heart Failure. Current Developments in Nutrition, 2020, 4, nzaa071.	0.3	20
49	Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease. American Heart Journal, 2016, 178, 28-36.	2.7	19
50	Prevalence and Incidence of Atrial Fibrillation in Ambulatory Patients With Heart Failure. American Journal of Cardiology, 2019, 124, 1554-1560.	1.6	19
51	Contractile Dysfunction in Sarcomeric Hypertrophic Cardiomyopathy. Journal of Cardiac Failure, 2016, 22, 731-737.	1.7	18
52	Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe. Heart, 2019, 105, 1252-1259.	2.9	18
53	Chronic Obstructive Pulmonary Disease and Heart Failure. Heart Failure Clinics, 2020, 16, 33-44.	2.1	18
54	Does home oxygen benefit people with chronic heart failure?. BMJ: British Medical Journal, 2011, 342, d234-d234.	2.3	17

#	Article	IF	CITATIONS
55	Inâ€hospital worsening heart failure: a clinically relevant endpoint?. ESC Heart Failure, 2018, 5, 9-18.	3.1	16
56	Biomarkerâ€based assessment of collagen crossâ€linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the <scp>HOMAGE</scp> clinical trial. European Journal of Heart Failure, 2022, 24, 321-331.	7.1	16
57	Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the <scp>SilHF</scp> study): a randomized placeboâ€controlled multicentre trial. European Journal of Heart Failure, 2022, 24, 1239-1248.	7.1	16
58	Clinical trials update from the European Society of Cardiology–Heart Failure meeting 2015: <scp>AUGMENTâ€HF</scp> , <scp>TITRATION</scp> , <scp>STOPâ€HF</scp> , <scp>HARMONIZE</scp> , <scp>LION HEART</scp> , <scp>MOODâ€HF</scp> , and renin–angiotensin inhibitors in patients with heart and renal failure. European Journal of Heart Failure, 2015, 17, 979-983.	7.1	15
59	The impact of heart failure and chronic obstructive pulmonary disease on mortality in patients presenting with breathlessness. Clinical Research in Cardiology, 2019, 108, 185-193.	3.3	15
60	Prevention or Procrastination for HeartÂFailure?. Journal of the American College of Cardiology, 2019, 73, 2398-2400.	2.8	15
61	The prevalence and clinical associations of ultrasound measures of congestion in patients at risk of developing heart failure. European Journal of Heart Failure, 2021, 23, 1831-1840.	7.1	14
62	Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure. European Journal of Heart Failure, 2000, 2, 107-112.	7.1	12
63	Exercise and heart failure: assessment and treatment. Heart, 2006, 92, 699-703.	2.9	12
64	The relationship of QRS morphology with cardiac structure and function in patients with heart failure. Clinical Research in Cardiology, 2015, 104, 935-945.	3.3	12
65	Outcome of hospitalised heart failure in Japan and the United Kingdom stratified by plasma N-terminal pro-B-type natriuretic peptide. Clinical Research in Cardiology, 2018, 107, 1103-1110.	3.3	12
66	The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial. European Journal of Heart Failure, 2022, 24, 1559-1568.	7.1	12
67	Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 82-92.	3.0	11
68	Is Cardiorespiratory Fitness Related to Cardiometabolic Health and All-Cause Mortality Risk in Patients with Coronary Heart Disease? A CARE CR Study. Sports Medicine - Open, 2018, 4, 22.	3.1	11
69	ldentification of sexâ€specific biomarkers predicting newâ€onset heart failure. ESC Heart Failure, 2021, 8, 3512-3520.	3.1	11
70	Body mass, chronic heart failure, surgery and survival. Journal of Heart and Lung Transplantation, 2010, 29, 261-264.	0.6	10
71	If home telemonitoring reduces mortality in heart failure, is this just due to better guideline-based treatment?. Journal of Telemedicine and Telecare, 2015, 21, 331-339.	2.7	10
72	How big a problem is heart failure with a normal ejection fraction?. BMJ, The, 2016, 353, i1706.	6.0	10

#	Article	IF	CITATIONS
73	Mortality after admission for heart failure in the UK compared with Japan. Open Heart, 2018, 5, e000811.	2.3	10
74	Electrocardiographic characteristics in patients with heart failure and normal ejection fraction: A systematic review and metaâ€analysis. Annals of Noninvasive Electrocardiology, 2020, 25, e12710.	1.1	10
75	<cardiovascular clinical="" data<="" emerging="" failure:="" heart="" in="" outcomes="" p="" sacubitril-valsartan="" with="">. Therapeutics and Clinical Risk Management, 2020, Volume 16, 715-726.</cardiovascular>	2.0	10
76	Serum and urinary biomarkers of collagen typeâ€i turnover predict prognosis in patients with heart failure. Clinical and Translational Medicine, 2021, 11, e267.	4.0	10
77	Do patients with chronic heart failure have chest pain?. International Journal of Cardiology, 2013, 167, 185-189.	1.7	9
78	Pharmacological and Non-pharmacological Treatment for Decompensated Heart Failure: What Is New?. Current Heart Failure Reports, 2017, 14, 147-157.	3.3	9
79	Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 469-477.	4.0	9
80	Is the diagnostic coding position of acute heart failure related to mortality? A report from the Euro Heart Failure Surveyâ€1. European Journal of Heart Failure, 2016, 18, 556-563.	7.1	8
81	CARE CR-Cardiovascular and cardiorespiratory Adaptations to Routine Exercise-based Cardiac Rehabilitation: a study protocol for a community-based controlled study with criterion methods. BMJ Open, 2018, 8, e019216.	1.9	8
82	Are there patients missing from community heart failure registers? An audit of clinical practice. European Journal of Preventive Cardiology, 2019, 26, 291-298.	1.8	8
83	Prognostic value of the chest X-ray in patients hospitalised for heart failure. Clinical Research in Cardiology, 2021, 110, 1743-1756.	3.3	8
84	Regional circulatory distribution of novel cardiac bio-markers and their relationships with haemodynamic measurements. International Journal of Cardiology, 2016, 210, 149-155.	1.7	7
85	Postmortem ICD interrogation in mode of death classification. Journal of Cardiovascular Electrophysiology, 2018, 29, 573-583.	1.7	7
86	Effect of beta-adrenergic blockade on weight changes in patients with chronic heart failure. International Journal of Cardiology, 2018, 264, 104-112.	1.7	7
87	Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry. ESC Heart Failure, 2020, 7, 727-736.	3.1	7
88	Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. Cardiovascular Diabetology, 2021, 20, 163.	6.8	7
89	Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the <scp>HOMAGE</scp> trial. European Journal of Heart Failure, 2022, 24, 771-778.	7.1	7
90	Chronic Obstructive Pulmonary Disease and Heart Failure. Cardiology Clinics, 2022, 40, 171-182.	2.2	7

#	Article	IF	CITATIONS
91	A comparison of nonâ€invasive methods of measuring body composition in patients with heart failure: a report from SICAâ€HF. ESC Heart Failure, 2021, 8, 3929-3934.	3.1	6
92	Clinical trials update from the European Society of Cardiology meeting 2014: PARADIGMâ€HF, CONFIRMâ€HF, SIGNIFY, atrial fibrillation, betaâ€blockers and heart failure, and vagal stimulation in heart failure. ESC Heart Failure, 2014, 1, 82-86.	3.1	5
93	Lipid-Modifying Treatments for Heart Failure. Heart Failure Clinics, 2014, 10, 621-634.	2.1	5
94	This patient is not breathing properly: is this COPD, heart failure, or neither?. Expert Review of Cardiovascular Therapy, 2017, 15, 389-396.	1.5	5
95	Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure. International Journal of Cardiology, 2017, 238, 97-104.	1.7	5
96	Clinical and prognostic relationships of pulmonary artery to aorta diameter ratio in patients with heart failure: a cardiac magnetic resonance imaging study. Clinical Cardiology, 2018, 41, 20-27.	1.8	5
97	Relationship between a single measurement at baseline of body mass index, glycated hemoglobin, and the risk of mortality and cardiovascular morbidity in type 2 diabetes mellitus. Cardiovascular Endocrinology and Metabolism, 2020, 9, 177-182.	1.1	5
98	Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from <scp>HOMAGE</scp> and the <scp>UK</scp> Biobank. European Journal of Heart Failure, 2022, 24, 976-984.	7.1	5
99	Influence of case definition on incidence and outcome of acute coronary syndromes. Open Heart, 2016, 3, e000487.	2.3	4
100	The effect of increasing inspired oxygen on exercise performance in patients with chronic heart failure. Heart, 2016, 102, 597-601.	2.9	4
101	Effect of increased inspired oxygen on exercise performance in patients with heart failure and normal ejection fraction. International Journal of Cardiology, 2018, 268, 166-169.	1.7	4
102	Clinical and prognostic association of total atrial conduction time in patients with heart failure. Journal of Cardiovascular Medicine, 2019, 20, 442-449.	1.5	4
103	Relation Between Thyroid Function and Mortality in Patients With Chronic Heart Failure. American Journal of Cardiology, 2021, 139, 57-63.	1.6	4
104	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	3.0	4
105	What impact do anxiety, depression, perceived control and technology capability have on whether patients with chronic heart failure take-up or continue to use home tele-monitoring services? Study design of ADaPT-HF. European Journal of Cardiovascular Nursing, 2017, 16, 283-289.	0.9	3
106	Impact of Malnutrition Using Geriatric Nutritional Risk Index in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 676-677.	4.1	3
107	The effect of digoxin on renal function in patients with heart failure. BMC Nephrology, 2021, 22, 349.	1.8	3
108	The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial. Journal of Cardiac Failure, 2021, , .	1.7	3

#	Article	IF	CITATIONS
109	Almanac 2011: heart failure. The national society journals present selected research that has driven recent advances in clinical cardiology. Heart, 2011, 97, 1643-1649.	2.9	2
110	Interatrial shunt devices for heart failure with normal ejection fraction: a technology update. Medical Devices: Evidence and Research, 2017, Volume 10, 123-132.	0.8	2
111	Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects. International Journal of General Medicine, 2021, Volume 14, 7797-7805.	1.8	2
112	Treating sarcopenia: the LACE trial. Journal of Cachexia, Sarcopenia and Muscle, 2022, , .	7.3	2
113	Exploring the relation between changes in NT-proBNP and renal function in patients with suspected heart failure using structural equation modelling. International Journal of Cardiology, 2017, 233, 67-72.	1.7	1
114	Cardiogoniometry Compared to Fractional Flow Reserve at Identifying Physiologically Significant Coronary Stenosis: The CARDIOFLOW Study. Cardiovascular Engineering and Technology, 2018, 9, 439-446.	1.6	1
115	Warm water immersion in patients with chronic heart failure: a pilot study. Clinical Research in Cardiology, 2019, 108, 468-476.	3.3	1
116	Driving Habits and Reaction Times on a Driving Simulation in Older Drivers With Chronic Heart Failure. Journal of Cardiac Failure, 2020, 26, 555-563.	1.7	1
117	Silent broken heart (Can shortness of breath be the only presentation of myocardial infarction?). BMJ Case Reports, 2015, 2015, bcr2014207689.	0.5	1
118	Can the transfer function method of assessing baroreflex sensitivity predict outcome in heart failure patients?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 76-77.	3.3	0
119	Almanac 2011: heart failure. The national society journals present selected research that has driven recent advances in clinical cardiology. Revista Portuguesa De Cardiologia, 2011, 30, 941-948.	0.5	0
120	53â€Heart Rate as a Therapeutic Target in Heart Failure: Analysis of 1000 Consecutive Outpatient Appointments to a Heart Failure Clinic. Heart, 2014, 100, A30.2-A31.	2.9	0
121	Almanac 2013: heart failure. Anatolian Journal of Cardiology, 2014, 14, 313-318.	0.4	Ο
122	New pharmacological approaches in heart failure therapy: developments and possibilities. Future Cardiology, 2017, 13, 173-188.	1.2	0
123	152â€Does outpatient based IV diuretic treatment for acute heart failure give patients hope?. , 2021, , .		0
124	Q&A: Hypertension part 1. Independent Nurse, 2005, 2005, .	0.1	0
125	Q&A: Hypertension part 2. Independent Nurse, 2005, 2005, .	0.1	0
126	Q&A: Hypertension part 3. Independent Nurse, 2005, 2005, .	0.1	0

#	Article	IF	CITATIONS
127	Q&A: Cardiology. Independent Nurse, 2005, 2005, .	0.1	0
128	Back to the future?. Heart Failure Monitor, 2003, 3, 151-6.	0.7	0
129	Almanac 2011: heart failure. The national society journals present selected research that has driven recent advances in clinical cardiology. Turk Kardiyoloji Dernegi Arsivi, 2011, 39, 611-20.	0.5	0
130	Uzman Yanıtları. Turk Kardiyoloji Dernegi Arsivi, 2014, 42, 94-101.	0.5	0